Monday, 19 September 2016

TKIs competing for frontline therapy in ALK+ NSCLC

Deciding the sequencing order of therapies for patients with ALK-positive non–small cell lung cancer (NSCLC) is a challenge, as new information on next-generation tyrosine kinase inhibitors (TKIs) comes to light.

Options and outcomes for various TKIs were discussed during the Physicians’ Education Resource (PER®) seminar “Oncogenic Tumor Board in NSCLC: Targeting Driver Mutations to Maximize Therapeutic Outcomes,” which took place during the 2016 ASCO Annual Meeting in Chicago.

Please read more here.

No comments:

Post a Comment